Applications of TCR repertoire as a biomarker for immunotherapy and beyond
Available On Demand
Speaker: Dr. Ankita Das
If you’ve already registered, please click here to log in to the webcast.
Checkpoint inhibitors have produced durable responses, even cure, in patients who have failed all therapies. This phenomenon is unprecedented in cancer treatment, revitalizing efforts to expand their use in a greater % of patients. Many tumor cell-intrinsic and extrinsic factors influence the magnitude of anti-tumor immunity influencing long-term survival. CD8 T cell infiltration, their spatial distribution within the tumor, and tumor mutation burden have led to a broader classification of tumors: a) “hot” - high infiltration of T cells including CD8; b) “cold”: lack of T cell infiltration including CD8; c) “excluded”: presence of T cells in the periphery of the tumor but no infiltration in the tumor core, and d) “ intermediate or suppressed”: some infiltration but no anti-tumor activity.
TCR repertoire profiling is routinely used for monitoring immune response and is gaining utility in cancer immunotherapy applications. In this webinar, I will discuss various tools that MedGenome has created to study the T cell phenotype, their activation state and their target neoantigen to enable biomarker discovery and define potential therapeutic strategies.
Highlights of the presentation
- Overview of tumor microenvironment analysis using OncoPeptTUME
- TCR repertoire analysis platform OncoPeptTCR
- TCR analysis from FFPE tissue
- Gamma/ Delta TCR repertoire analysis
- Emerging areas of knowledge in the TCR space
This webcast has been produced by the Advertiser, MedGenome Inc. who retains sole responsibility for content. About this content
